- Home
- PCN vs QURE Comparison
PCN vs QURE Comparison
Compare PCN & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCN
- QURE
- Stock Information
- Founded
- PCN 2001
- QURE 1998
- Country
- PCN United States
- QURE Netherlands
- Employees
- PCN N/A
- QURE N/A
- Industry
- PCN Investment Managers
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- PCN Finance
- QURE Health Care
- Exchange
- PCN Nasdaq
- QURE Nasdaq
- Market Cap
- PCN 802.3M
- QURE 725.4M
- IPO Year
- PCN N/A
- QURE 2007
- Fundamental
- Price
- PCN $12.59
- QURE $15.11
- Analyst Decision
- PCN
- QURE Strong Buy
- Analyst Count
- PCN 0
- QURE 10
- Target Price
- PCN N/A
- QURE $37.20
- AVG Volume (30 Days)
- PCN 218.7K
- QURE 1.0M
- Earning Date
- PCN 01-01-0001
- QURE 07-29-2025
- Dividend Yield
- PCN 9.73%
- QURE N/A
- EPS Growth
- PCN N/A
- QURE N/A
- EPS
- PCN N/A
- QURE N/A
- Revenue
- PCN N/A
- QURE $20,201,000.00
- Revenue This Year
- PCN N/A
- QURE N/A
- Revenue Next Year
- PCN N/A
- QURE $278.91
- P/E Ratio
- PCN N/A
- QURE N/A
- Revenue Growth
- PCN N/A
- QURE 6.30
- 52 Week Low
- PCN $10.70
- QURE $4.45
- 52 Week High
- PCN $14.48
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- PCN 46.88
- QURE 54.26
- Support Level
- PCN $12.46
- QURE $13.61
- Resistance Level
- PCN $12.60
- QURE $15.49
- Average True Range (ATR)
- PCN 0.06
- QURE 0.80
- MACD
- PCN -0.00
- QURE 0.08
- Stochastic Oscillator
- PCN 43.10
- QURE 68.27
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.